A detailed history of Price T Rowe Associates Inc transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 1,187,910 shares of KROS stock, worth $78.9 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,187,910
Previous 1,218,504 2.51%
Holding current value
$78.9 Million
Previous $80.7 Million 32.7%
% of portfolio
0.01%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$44.58 - $66.89 $1.36 Million - $2.05 Million
-30,594 Reduced 2.51%
1,187,910 $54.3 Million
Q1 2024

May 15, 2024

BUY
$41.26 - $70.48 $7.29 Million - $12.5 Million
176,803 Added 16.97%
1,218,504 $80.7 Million
Q4 2023

Feb 14, 2024

SELL
$27.12 - $41.05 $6.12 Million - $9.26 Million
-225,531 Reduced 17.8%
1,041,701 $41.4 Million
Q3 2023

Nov 14, 2023

SELL
$31.57 - $43.02 $98,782 - $134,609
-3,129 Reduced 0.25%
1,267,232 $40.4 Million
Q2 2023

Aug 14, 2023

BUY
$37.26 - $51.01 $4.39 Million - $6.01 Million
117,845 Added 10.23%
1,270,361 $51 Million
Q1 2023

May 15, 2023

BUY
$41.44 - $59.32 $22 Million - $31.5 Million
531,327 Added 85.53%
1,152,516 $49.2 Million
Q4 2022

Feb 14, 2023

BUY
$39.45 - $51.77 $24.1 Million - $31.7 Million
611,459 Added 6284.27%
621,189 $29.8 Million
Q3 2022

Nov 14, 2022

BUY
$27.8 - $40.12 $270,494 - $390,367
9,730 New
9,730 $367,000
Q2 2022

Aug 15, 2022

SELL
$26.03 - $67.04 $117,265 - $302,015
-4,505 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$42.12 - $59.36 $86,851 - $122,400
-2,062 Reduced 31.4%
4,505 $245,000
Q4 2021

Feb 14, 2022

BUY
$36.95 - $62.89 $242,650 - $412,998
6,567 New
6,567 $384,000

Others Institutions Holding KROS

About Keros Therapeutics, Inc.


  • Ticker KROS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,757,000
  • Market Cap $1.71B
  • Description
  • Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...
More about KROS
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.